Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library

Journal of Immunology

Volumn 157, Issue 2, 1996, Pages 884-891

  Sahu, Arvind ^a   Kay, Brian K ^b   Lambris, John D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3D; PROPERDIN;

ALKYLATION; AMINO TERMINAL SEQUENCE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT FIXATION; COMPLEMENT INHIBITION; HUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DEGRADATION; REDUCTION; SERUM;

AMINO ACID SEQUENCE; BACTERIOPHAGES; BINDING, COMPETITIVE; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT C3B; COMPLEMENT FACTOR B; COMPLEMENT INACTIVATOR PROTEINS; GENE LIBRARY; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PROPERDIN; PROTEIN BINDING;

EID: 0030013492     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Lambris, J. D. 1993. Chemistry, biology and phylogeny of C3. Complement Profiles 1:16 (Rev.).
2. Vriesendorp, F. J., R. E. Flynn, M. A. Pappolla, and C. L. Koski. 1995. Complement depletion affects demyelination and inflammation in experimental allergic neuritis. J. Neuroimmunol. 58:157.
3. Watson, W. C., and A. S. Townes. 1985. Genetic susceptibility to murine collagen II autoimmune arthritis. J. Exp. Med. 162:1878.
4. Nakano, S., and A. G. Engel. 1993. Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients. Neurology 43:1167.
5. Barohn, R. J., and R. L. Brey. 1993. Soluble terminal complement components in human myasthenia gravis. Clin. Neurol. Neurosurg. 95:285.
6. Schreiber, A. D., and M. M. Frank. 1972. Role of antibody and complement in the immune clearance and destruction of erythrocytes. I. In vivo effects of IgG and IgM complement-fixing sites. J. Clin. Invest. 51:575.
7. McLean, R. H. 1993. Complement and glomerulonephritis: an update. Pediatr. Nephrol. 7:226.
8. Cochrane, C. G. 1984. The role of complement in experimental disease models. Springer Semin. Immunopathol. 7:263.
9. Robbins, R. A., W. D. Russ, J. K. Rasmussen, and M. M. Clayton. 1987. Activation of the complement system in the adult respiratory distress syndrome. Am. Rev. Respir. Dis. 135:651.
10. Vasthare, U. S., R. H. Rosenwasser, F. C. Barone, and R. F. Tuma. 1993. Involvement of the complement system in cerebral ischemic and reperfusion injury. FASEB J. 7:A424.
11. Kilgore, K. S., G. S. Friedrichs, J. W. Homeister, and B. R. Lucchesi. 1994. The complement system in myocardial ischaemia/reperfusion injury. Cardiovasc. Res. 28:437.
12. Wang, M. W., P. S. Johnston, L. J. Wright, S. M. L. Lim, and D. J. G. White. 1992. Immunofluorescent localization of pig complement component-3, regardless of the presence or absence of detectable immunoglobulins, in hyperacutely rejected heart xenografts. Histochem. J. 24:102.
13. Leventhal, J. R., A. P. Dalmasso, J. W. Cromwell, J. L. Platt, C. I. Manivel, R. M. Bolman, and A. J. Matas. 1993. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation 55:857.
14. Williams, K. C., E. Ulvestad, and W. I. Hickey. 1994. Immunology of multiple sclerosis. Clin. Neurosci. 2:229.
15. Gallinaro, R., W. G. Cheadle, K. Applegate, and H. C. J. Polk. 1992. The role of the complement system in trauma and infection. Surg. Gynecol. Obstet. 174:435.
16. Pekna, M., L. Nilsson, K. Nilssonekdahl, U. R. Nilsson, and B. Nilsson. 1993. Evidence for iC3 generation during cardiopulmonary bypass as the result of blood-gas interaction. Clin. Exp. Immunol. 91:404.
17. Ehrengruber, M. U., T. Geiser, and D. A. Deranleau. 1994. Activation of human neutrophils by C3a and C5a: comparison of the effects on shape changes, chemotaxis, secretion, and respiratory burst. FEBS Lett. 346:181.
18. Ellati, S. G., C. A. Dahinden, and M. K. Church. 1994. Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J. Invest. Dermatol. 102:803.
19. Smedly, L. A., M. G. Tonnesen, R. A. Sandhaus, C. Haslett, L. A. Guthrie, R. B. J. Johnston, P. M. Henson, and G. S. Worthen. 1986. Neutrophil-mediated injury to endothelial cells: enhancement by endotoxin and essential role of neutrophil elastase. J. Clin. Invest. 77:1233.
20. Kalli, K. R., P. Hsu, and D. T. Fearon. 1994. Therapeutic uses of recombinant complement protein inhibitors. Springer Semin. Immunopathol. 15:417.
21. Scott, J. K., and G. P. Smith. 1990. Searching for peptide ligands with an epitope library. Science 249:386.
22. Sparks, A. B., L. A. Quilliam, J. M. Thorn, C. J. Der, and B. K. Kay. 1994. Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries. J. Biol. Chem. 269:23853.
23. Blond-Elguindi, S., S. E. Cwirla, W. J. Dower, R. J. Lipshutz, S. R. Sprang, J. F. Sambrook, and M. H. Gething. 1993. Affinity panning of a library of peptides displayed on bacteriophages reveals the binding specificity of BiP. Cell 75:717.
24. Dedman, J. R., M. A. Kaetzel, H. C. Chan, D. J. Nelson, and G. A. J. Jamieson. 1993. Selection of targeted biological modifiers from a bacteriophage library of random peptides: the identification of novel calmodulin regulatory peptides. J. Biol. Chem. 268:23025.
25. Devlin, J. J., L. C. Panganiban, and P. E. Devlin. 1990. Random peptide libraries: a source of specific protein binding molecules. Science 245:404.
26. Hammer, C. H., G. H. Wirtz, L. Renfer, H. D. Gresham, and B. F. Tack. 1981. Large scale isolation of functionally active components of the human complement system. J. Biol. Chem. 256:3995.
27. Alsenz, J., D. Avila, H. P. Huemer, I. Esparza, J. D. Becherer, T. W. Kinoshita, Y. S. Oppermann, and J. D. Lambris. 1992. Phylogeny of the third component of complement, C3: analysis of the conservation of human CR1, CR2, H, and B binding sites, Concanavalin A binding sites, and thiolester bond in the C3 from different species. Dev. Comp. Immunol. 16:63.
28. Lambris, J. D., and H. J. Muller-Eberhard. 1984. Isolation and characterization of a 33,000-dalton fragment of complement factor B with catalytic and C3b binding activity. J. Biol. Chem. 259:12685.
29. Alsenz, J., T. F. Schulz, J. D. Lambris, R. B. Sim, and M. P. Dierich. 1985. Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H. Biochem. J. 232:841.
30. Hsiung, L.-M., A. N. Barclay, M. R. Brandon, E. Sim, and R. R. Porter. 1982. Purification of human C3b inactivator by monoclonal-antibody affinity chromatography. Biochem. J. 203:293.
31. Pangburn, M. K. 1987. A fluorometric assay for native C3: the hemolytically active form of the third component of human complement. J. Immunol. Methods 102:7.
32. Becherer, J. D., and J. D. Lambris. 1988. Identification of the C3b receptor-binding domain in third component of complement. J. Biol. Chem. 263:14586.
33. Erdei, A., F. Melchers, T. Schulz, and M. Dierich. 1985. The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. Eur. J. Immunol. 15:184.
34. Kay, B. K., N. B. Adey, Y.-S. He, J. P. Manfredi, A. H. Mataragnon, and D. M. Fowlkes. 1993. An M13 phage library displaying random 38-amino acid peptides as a source of novel sequences with affinity to select targets. Gene 128:59.
35. Adey, N., and B. Kay. 1996. Identification of calmodulin-binding peptide consensus sequences from a phage-displayed random peptide library. Gene 169:133.
36. Kay, B. K. 1995. Mapping protein-protein interactions with biologically expressed random peptide libraries. Persp. Drug Discovery Design 2:251.
37. Sanger, F. S., S. Nicklen, and A. R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA 74:5463.
38. Moore, W. T. 1993. Integration of mass spectrometry into strategies for peptide synthesis. Biol. Mass Spectrom. 22:149.
39. Angeletti, R. H., L. Bibbs, L. F. Bonewald, G. B. Fields, J. S. McMurray, W. T. Moore, and J. T. Stults. 1996. Formation of disulfide bond in an octreotide-like peptide: a multicenter study. In Techniques in Protein Chemistry, Vol. 7. D. R. Marshak, ed. Academic Press, San Diego, p. 261.
40. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 277:680.
41. Daoudaki, M. E., J. D. Becherer, and J. D. Lambris. 1988. A 34-amino acid peptide of the third component of complement mediates properdin binding [published erratum appears in J. Immunol. 141:1788].
42. Glover, G., C. S. Schasteen, W. S. Liu, and R. P. Levine. 1988. Synthetic peptide inhibitors of complement serine proteases. I. Identification of functionally equivalent protease inhibitor sequences in serpins and inhibition of Cls and D. Mol. Immunol. 25:1261.
43. Schasteen, C. S., R. P. Levine, S. A. McLafferty, R. F. Finn, L. D. Bullock, J. C. Mayden, and G. I. Glover. 1991. Synthetic peptide inhibitors of complement serine proteases. III. Significant increase in inhibitor potency provides further support for the functional equivalence hypothesis. Mol. Immunol. 28:17.
44. Kam, C. M., T. J. Oglesby, M. K. Pangburn, J. E. Volanakis, and J. C. Powers. 1992. Substituted isocoumarins as inhibitors of complement serine proteases. J. Immunol. 149:163.
45. Aoyama, T., Y. Ino, M. Ozeki, M. Oda, T. Sato, Y. Koshiyama, S. Suzuki, and M. Fujita. 1984. Pharmacological studies of FUT-175, nafamstat mesilate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn. J. Pharmacol. 35:203.
46. Laura, R., D. J. Robison, and D. H. Bing. 1980. (p-Amidinophenyl) methane-sulfonyl fluoride, an irreversible inhibitor of serine proteases. Biochemistry 19: 4859.
47. Sahu, A., and M. K. Pangburn. 1996. Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. Biochem. Pharmacol. 51:797.
48. Becherer, J. D., J. Alsenz, and J. D. Lambris. 1989. Molecular aspects of C3 interactions and structural/functional analysis of C3 from different species. Curr. Top. Microbiol. Immunol. 153:45 (Rev.).
49. Sim, R. B., T. M. Twose, D. S. Paterson, and E. Sim. 1981. The covalent-binding reaction of complement component C3. Biochem. J. 193:115.
50. Sim, E., E. W. Gill, and R. B. Sim. 1984. Drugs which induce systemic lupus erythematosus inhibit complement component C4. Lancet 2:422.
51. Luzzago, A., F. Felici, A. Tramontano, A. Pessi, and R. Cortese. 1993. Mimicking of discontinuous epitopes by phage-displayed peptides. I. Epitope mapping of human H ferritin using a phage library of constrained peptides. Gene 128:51.
52. Kremser, A., and I. Rasched. 1994. The adsorption of filamentous phage fd: assignment of its disulfide bridges and identification of the domain incorporated in the coat. Biochemistry 33:13954.
53. Holers, V. M., T. Kinoshita, and H. Molina. 1992. The evolution of mouse and human complement C3-binding proteins: divergence of form but conservation of function. Immunol. Today 13:231.